دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
New Therapeutic Targets in Antineutrophil Cytoplasm Antibody–Associated Vasculitis
Maria Prendecki Stephen P. McAdoo
doi : 10.1002/art.41407
Arthritis & RheumatologyVolume 73, Issue 3 p. 361-370
Antineutrophil cytoplasm antibody (ANCA)–associated vasculitis (AAV) is a rare systemic autoimmune disease that is characterized by necrotizing inflammation of predominantly the small blood vessels and the presence of circulating ANCAs directed against myeloperoxidase or proteinase 3. Current treatment strategies for severe disease, supported by the findings of several well?coordinated randomized controlled trials, aim to induce remission with high?dose glucocorticoids and either rituximab or cyclophosphamide, followed by relapse prevention with a period of sustained low?dose treatment. This approach has dramatically improved outcomes in AAV; however, a significant proportion of patients develop serious treatment?related side effects or experience relapse. Recent advances in our understanding of the pathogenesis of AAV have led to the identification of novel therapeutic targets that may address these problems, including strategies directed at the aberrant adaptive autoimmune response (B and T cell–directed treatments) and those targeting innate immune elements (complement, monocytes, and neutrophils). It is anticipated that these novel treatments, used alone or in combination, will lead to more effective and less toxic treatment regimens for patients with AAV.
Acupuncture and Knee Osteoarthritis: Does Dose Matter?
David J. Hunter Richard E. Harris
doi : 10.1002/art.41583
Arthritis & RheumatologyVolume 73, Issue 3 p. 371-373
Association of Race and Ethnicity With COVID?19 Outcomes in Rheumatic Disease: Data From the COVID?19 Global Rheumatology Alliance Physician Registry
Milena A. Gianfrancesco Liza A. Leykina Zara Izadi Tiffany Taylor Jeffrey A. Sparks Carly Harrison Laura Trupin Stephanie Rush Gabriela Schmajuk Patricia Katz Lindsay Jacobsohn Tiffany Y. Hsu Kristin M. D’Silva Naomi Serling?Boyd Rachel Wallwork Derrick J. Todd Suleman Bhana Wendy Costello Rebecca Grainger Jonathan S. Hausmann Jean W. Liew Emily Sirotich Paul Sufka Zachary S. Wallace Pedro M. Machado Philip C. Robinson Jinoos Yazdany the COVID?19 Global Rheumatology Alliance
doi : 10.1002/art.41567
Arthritis & RheumatologyVolume 73, Issue 3 p. 374-380
Racial/ethnic minorities experience more severe outcomes of coronavirus disease 2019 (COVID?19) in the general US population. This study was undertaken to examine the association between race/ethnicity and COVID?19 hospitalization, ventilation status, and mortality in people with rheumatic disease.
Allele?Specific Quantification of HLA–DRB1 Transcripts Reveals Imbalanced Allelic Expression That Modifies the Amino Acid Effects in HLA–DR?1
Sehwan Chun So?Young Bang Eunji Ha Jing Cui Ki?Nam Gu Hye?Soon Lee Kwangwoo Kim Sang?Cheol Bae
doi : 10.1002/art.41535
Arthritis & RheumatologyVolume 73, Issue 3 p. 381-391
HLA association fine?mapping studies have shown the effects of missense variants in HLA–DRB1 on rheumatoid arthritis (RA) susceptibility, prognosis, and autoantibody production. However, the phenotypic effects of expression changes in HLA–DRB1 remain poorly understood. Therefore, we investigated the allele?specific expression of HLA–DRB1 and its effect on an HLA–DR?1 structure–associated trait in RA.
Association of Agricultural, Occupational, and Military Inhalants With Autoantibodies and Disease Features in US Veterans With Rheumatoid Arthritis
Ariadne V. Ebel Gabrielle Lutt Jill A. Poole Geoffrey M. Thiele Joshua F. Baker Grant W. Cannon Angelo Gaffo Gail S. Kerr Andreas Reimold Pascale Schwab Namrata Singh J. Steuart Richards Dana P. Ascherman Ted R. Mikuls Bryant R. England
doi : 10.1002/art.41559
Arthritis & RheumatologyVolume 73, Issue 3 p. 392-400
To determine the association of inhalant exposures with rheumatoid arthritis (RA)–related autoantibodies and severity in US veterans.
Profiling of Serum Oxylipins During the Earliest Stages of Rheumatoid Arthritis
Javier Rodr?guez?Carrio Roxana Coras Mercedes Alperi?L?pez Patricia L?pez Catalina Ulloa Francisco Javier Ballina?Garc?a Aaron M. Armando Oswald Quehenberger M?nica Guma Ana Su?rez
doi : 10.1002/art.41537
Arthritis & RheumatologyVolume 73, Issue 3 p. 401-413
Eicosanoids modulate inflammation via complex networks involving different pathways and downstream mediators, including oxylipins. Although altered eicosanoids are linked to rheumatoid arthritis (RA), suggesting that metabolization is enhanced, the role of oxylipins in disease stratification remains unexplored. This study was undertaken to characterize oxylipin networks during the earliest stages of RA and evaluate their associations with clinical features and treatment outcomes.
Error in Statement on Carbonated Beverage Consumption in the Article by FitzGerald et al (Arthritis Rheumatol, June 2020)
John D. FitzGerald Nicola Dalbeth Ted Mikuls Romina Brignardello?Petersen Gordon Guyatt Aryeh M. Abeles Allan C. Gelber Leslie R. Harrold Dinesh Khanna Charles King Gerald Levy Caryn Libbey David Mount Michael H. Pillinger Ann Rosenthal Jasvinder A. Singh James Edward Sims Benjamin J. Smith Neil S. Wenger Sangmee Sharon Bae Abhijeet Danve Puja P. Khanna Seoyoung C. Kim Aleksander Lenert Samuel Poon Anila Qasim Shiv T. Sehra Tarun Sudhir Kumar Sharma Michael Toprover Marat Turgunbaev Linan Zeng Mary Ann Zhang Amy S. Turner Tuhina Neogi
doi : 10.1002/art.41688
Arthritis & RheumatologyVolume 73, Issue 3 p. 413-413
no abstract
Mechanosensitive Control of Articular Cartilage and Subchondral Bone Homeostasis in Mice Requires Osteocytic Transforming Growth Factor ? Signaling
Karsyn N. Bailey Jeffrey Nguyen Cristal S. Yee Neha S. Dole Alexis Dang Tamara Alliston
doi : 10.1002/art.41548
Arthritis & RheumatologyVolume 73, Issue 3 p. 414-425
Transforming growth factor ? (TGF?) signaling plays a complex tissue?specific and nonlinear role in osteoarthritis (OA). This study was conducted to determine the osteocytic contributions of TGF? signaling to OA.
MicroRNA?34a?5p Promotes Joint Destruction During Osteoarthritis
Helal Endisha Poulami Datta Anirudh Sharma Sayaka Nakamura Evgeny Rossomacha Carolen Younan Shabana A. Ali Ghazaleh Tavallaee Starlee Lively Pratibha Potla Konstantin Shestopaloff Jason S. Rockel Roman Krawetz Nizar N. Mahomed Igor Jurisica Rajiv Gandhi Mohit Kapoor
doi : 10.1002/art.41552
Arthritis & RheumatologyVolume 73, Issue 3 p. 426-439
MicroRNA?34a?5p (miR?34a?5p) expression is elevated in the synovial fluid of patients with late?stage knee osteoarthritis (OA); however, its exact role and therapeutic potential in OA remain to be fully elucidated. This study was undertaken to examine the role of miR?34a?5p in OA pathogenesis.
Familial Clustering of Erosive Hand Osteoarthritis in a Large Statewide Cohort
Nikolas H. Kazmers Huong D. Meeks Kendra A. Novak Zhe Yu Gail L. Fulde Joy L. Thomas Tyler Barker Michael J. Jurynec
doi : 10.1002/art.41520
Arthritis & RheumatologyVolume 73, Issue 3 p. 440-447
Erosive hand osteoarthritis (OA) is a severe and rapidly progressing subset of hand OA. Its etiology remains largely unknown, which has hindered development of successful treatments. This study was undertaken to test the hypothesis that erosive hand OA demonstrates familial clustering in a large statewide population linked to genealogical records, and to determine the association of potential risk factors with erosive hand OA.
Efficacy of Intensive Acupuncture Versus Sham Acupuncture in Knee Osteoarthritis: A Randomized Controlled Trial
Jian?Feng Tu Jing?Wen Yang Guang?Xia Shi Zhang?Sheng Yu Jin?Ling Li Lu?Lu Lin Yu?Zheng Du Xiao?Gang Yu Hui Hu Zhi?Shun Liu Chun?Sheng Jia Li?Qiong Wang Jing?Jie Zhao Jun Wang Tong Wang Yang Wang Tian?Qi Wang Na Zhang Xuan Zou Yu Wang Jia?Kai Shao Cun?Zhi Liu
doi : 10.1002/art.41584
Arthritis & RheumatologyVolume 73, Issue 3 p. 448-458
To assess the efficacy of intensive acupuncture (3 times weekly for 8 weeks) versus sham acupuncture for knee osteoarthritis (OA).
Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus
Kerry A. Casey Michael A. Smith Dominic Sinibaldi Nickie L. Seto Martin P. Playford Xinghao Wang Philip M. Carlucci Liangwei Wang Gabor Illei Binbing Yu Shiliang Wang Alan T. Remaley Nehal N. Mehta Mariana J. Kaplan Wendy I. White
doi : 10.1002/art.41518
Arthritis & RheumatologyVolume 73, Issue 3 p. 459-471
Neutrophil dysregulation and the type I interferon (IFN) axis have been proposed to contribute to premature cardiovascular disease, a leading cause of mortality in patients with systemic lupus erythematosus (SLE). In the present study, we evaluated the ability of anifrolumab, a type I IFN receptor–blocking antibody, to reduce neutrophil extracellular trap (NET) formation and modulate cardiometabolic disease markers in comparison to placebo.
Suppression of Serum Interferon?? Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus
Matteo Cesaroni Loqmane Seridi Matthew J. Loza Jessica Schreiter Kristen Sweet Carol Franks Keying Ma Ashley Orillion Kim Campbell Robert M. Gordon Patrick Branigan Peter Lipsky Ronald van Vollenhoven Bevra H. Hahn George C. Tsokos Marc Chevrier Shawn Rose Frédéric Baribaud Jarrat Jordan
doi : 10.1002/art.41547
Arthritis & RheumatologyVolume 73, Issue 3 p. 472-477
In a previously reported phase II randomized, placebo?controlled, interventional trial, we demonstrated that treatment with ustekinumab, an anti–interleukin?12 (IL?12)/IL?23 p40 neutralizing monoclonal antibody, improved global and organ?specific measures of disease activity in patients with active systemic lupus erythematosus (SLE). Utilizing the biomarker data from this phase II clinical study, we sought to determine whether modulation of the expression of IL?12, IL?23, or both cytokines by ustekinumab is associated with clinical efficacy in patients with SLE.
Type I Interferon–Activated STAT4 Regulation of Follicular Helper T Cell–Dependent Cytokine and Immunoglobulin Production in Lupus
Xuemei Dong Olivia Q. Antao Wenzhi Song Gina M. Sanchez Krzysztof Zembrzuski Fotios Koumpouras Alexander Lemenze Joe Craft Jason S. Weinstein
doi : 10.1002/art.41532
Arthritis & RheumatologyVolume 73, Issue 3 p. 478-489
To assess the role of STAT4 activation in driving pathogenic follicular helper T (Tfh) cell secretion of the cytokines interleukin?21 (IL?21) and interferon?? (IFN?) in murine and human lupus.
A Novel RELA Truncating Mutation in a Familial Behçet’s Disease–like Mucocutaneous Ulcerative Condition
Fahd Adeeb Emma R. Dorris Niamh E. Morgan Dylan Lawless Aqeel Maqsood Wan Lin Ng Orla Killeen Eoin P. Cummins Cormac T. Taylor Sinisa Savic Anthony G. Wilson Alexander Fraser
doi : 10.1002/art.41531
Arthritis & RheumatologyVolume 73, Issue 3 p. 490-497
Monogenic Behçet’s disease (BD)–like conditions are increasingly recognized and to date have been found to predominantly involve loss?of?function variants in TNFAIP3. This study was undertaken to identify genetic and pathobiologic mechanisms associated with a BD?like mucocutaneous ulcerative syndrome and neuromyelitis optica (NMO) occurring in 3 generations of an Irish family (n = 5 cases and 5 familial controls).
Use of Biologics to Treat Relapsing and/or Refractory Eosinophilic Granulomatosis With Polyangiitis: Data From a European Collaborative Study
Alice Canzian Nils Venhoff Maria Letizia Urban Silvia Sartorelli Anne?Marie Ruppert Matthieu Groh Nicolas Girszyn Camille Taillé François Maurier Vincent Cottin Claire de Moreuil Vincent Germain Maxime Samson Marie Jachiet Laure Denis Virginie Rieu Perrine Smets Grégory Pugnet Alban Deroux Cécile?Audrey Durel Achille Aouba Pascal Cathébras Christophe Deligny Stanislas Faguer Helder Gil Bertrand Godeau François Lifermann Sophie Phin?Huynh Marc Ruivard Philippe Bonniaud Xavier Puéchal Jean?Emmanuel Kahn Jens Thiel Lorenzo Dagna Loïc Guillevin Augusto Vaglio Giacomo Emmi Benjamin Terrier for the French Vasculitis Study Group and the European EGPA Study Group
doi : 10.1002/art.41534
Arthritis & RheumatologyVolume 73, Issue 3 p. 498-503
To describe the efficacy and safety of biologics for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA).
Cardiovascular and Renal Morbidity in Takayasu Arteritis: A Population?Based Retrospective Cohort Study From the United Kingdom
Ruchika Goel Joht Singh Chandan Rasiah Thayakaran Nicola J. Adderley Krishnarajah Nirantharakumar Lorraine Harper
doi : 10.1002/art.41529
Arthritis & RheumatologyVolume 73, Issue 3 p. 504-511
Cardiovascular disease (CVD) is a major complication and cause of mortality in Takayasu arteritis (TAK), but population?based controlled studies from the UK are lacking. We undertook the present study to investigate the frequency of morbidity and mortality related to CVD, as well as to cerebrovascular and kidney disease, among patients with TAK in the UK.
Sequence?Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in ADA2
Oskar Schnappauf Natalia Sampaio Moura Ivona Aksentijevich Monique Stoffels Amanda K. Ombrello Patrycja Hoffmann Karyl Barron Elaine F. Remmers Michael Hershfield Susan J. Kelly NISC Comparative Sequencing Program David Cuthbertson Simon Carette Sharon A. Chung Lindsy Forbess Nader A. Khalidi Curry L. Koening Carol A. Langford Carol A. McAlear Paul A. Monach Larry Moreland Christian Pagnoux Philip Seo Jason M. Springer Antoine G. Sreih Kenneth J. Warrington Steven R. Ytterberg Daniel L. Kastner Peter C. Grayson Peter A. Merkel for the Vasculitis Clinical Research Consortium
doi : 10.1002/art.41549
Arthritis & RheumatologyVolume 73, Issue 3 p. 512-519
Deficiency of adenosine deaminase 2 (DADA2) is a monogenic form of vasculitis that can resemble polyarteritis nodosa (PAN). This study was undertaken to identify potential disease?causing sequence variants in ADA2 in patients with idiopathic PAN, granulomatosis with polyangiitis (GPA), or microscopic polyangiitis (MPA).
Dissecting the Cellular Mechanism of Prostacyclin Analog Iloprost in Reversing Vascular Dysfunction in Scleroderma
Pei?Suen Tsou Pamela J. Palisoc Nicholas A. Flavahan Dinesh Khanna
doi : 10.1002/art.41536
Arthritis & RheumatologyVolume 73, Issue 3 p. 520-529
Intravenous iloprost improves Raynaud’s phenomenon (RP) and promotes healing of digital ulcers in systemic sclerosis (SSc; scleroderma). Despite a short half?life, its clinical efficacy lasts weeks. Endothelial adherens junctions, which are formed by VE?cadherin clustering between endothelial cells (ECs), regulate endothelial properties including barrier function, endothelial?to?mesenchymal transition (EndoMT), and angiogenesis. We undertook this study to investigate the hypothesis that junctional disruption contributes to vascular dysfunction in SSc, and that the protective effect of iloprost is mediated by strengthening of those junctions.
Efficacy and Safety of Tocilizumab for Polyarticular?Course Juvenile Idiopathic Arthritis in the Open?Label Two?Year Extension of a Phase III Trial
Hermine I. Brunner Nicolino Ruperto Zbigniew Zuber Rubén Cuttica Vladimir Keltsev Ricardo M. Xavier Ruben Burgos?Vargas Inmaculada Calvo Penades Earl D. Silverman Graciela Espada Manuel Ferrandiz Zavaler Yukiko Kimura Carolina Duarte Chantal Job?Deslandre Rik Joos Wendy Douglass Sunethra Wimalasundera Kamal N. Bharucha Chris Wells Daniel J. Lovell Alberto Martini Fabrizio de Benedetti for the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)
doi : 10.1002/art.41528
Arthritis & RheumatologyVolume 73, Issue 3 p. 530-541
To report the 2?year efficacy and safety of tocilizumab (TCZ) in patients with polyarticular?course juvenile idiopathic arthritis (JIA).
An Unusual Case of Proximal Limb Muscle Weakness
Despina Michailidou Sarah Chung James S. Andrews Gordon A. Starkebaum Felix S. Chew Caitlin S. Latimer
doi : 10.1002/art.41626
Arthritis & RheumatologyVolume 73, Issue 3 p. 541-541
Trends in Utilization of Urate?Lowering Therapies Following the US Food and Drug Administration’s Boxed Warning on Febuxostat
Seoyoung C. Kim Tuhina Neogi Erin Kim Joyce Lii Rishi J. Desai
doi : 10.1002/art.41550
Arthritis & RheumatologyVolume 73, Issue 3 p. 542-543
Treat?to?Target in Gout Management? Comment on the Article by FitzGerald et al
Michael R. Kolber Joey Ton
doi : 10.1002/art.41523
Arthritis & RheumatologyVolume 73, Issue 3 p. 543-544
Reply
Tuhina Neogi Nicola Dalbeth Ted R. Mikuls Amy S. Turner John D. FitzGerald
doi : 10.1002/art.41522
Arthritis & RheumatologyVolume 73, Issue 3 p. 544-545
Anti?Th/To Antibodies: Association With Lung Disease and Potential Protection From Systemic Sclerosis–Related Cancer? Comment on the Article by Mecoli et al
Michael Mahler Minoru Satoh Marvin Fritzler
doi : 10.1002/art.41560
Arthritis & RheumatologyVolume 73, Issue 3 p. 545-546
Further Investigation of Representation of Women as Authors of Rheumatology Articles From 2005 to 2020: Comment on the Article by Bagga et al
Jennifer Velasco Shikha Singla Michael Putman Abigail A. Thorgerson Elizabeth Suelzer Courtney B. Crayne
doi : 10.1002/art.41573
Arthritis & RheumatologyVolume 73, Issue 3 p. 546-547
Use of Apremilast in Patients With Psoriatic Arthritis During the COVID?19 Pandemic: Comment on the Article by Mikuls et al
Pankaj Bansal Amandeep Goyal Austin Cusick Fawad Aslam
doi : 10.1002/art.41575
Arthritis & RheumatologyVolume 73, Issue 3 p. 547-548
Reply
Ted R. Mikuls Liana Fraenkel Ellen Gravallese Sindhu R. Johnson Amy Turner Kenneth G. Saag
doi : 10.1002/art.41574
Arthritis & RheumatologyVolume 73, Issue 3 p. 548-549
Anakinra in COVID?19—How to Interpret Elevations of Serum Liver Enzymes: Comment on the Article by Navarro?Mill?n et al
Giulio Cavalli Lorenzo Dagna
doi : 10.1002/art.41525
Arthritis & RheumatologyVolume 73, Issue 3 p. 549-549
Reply
Iris Navarro?Mill?n Mary K. Crow
doi : 10.1002/art.41524
Arthritis & RheumatologyVolume 73, Issue 3 p. 549-550
